Titel

Merkliste
1 Ergebnisse

Efficacy and safety of MIL60 compared with bevacizumab in a..:

Rui Wan ; Xiaorong Dong ; Qun Chen...
http://www.sciencedirect.com/science/article/pii/S2589537021004685. , 2021

Link: https://doi.org/10.1016/j.eclinm.2021.101187

RT Journal
T1 <Title>Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:fdbc7c412b564497a8805b161236dd76&Exemplar=1&LAN=DE
				
A1 Rui Wan
A1 Xiaorong Dong
A1 Qun Chen
A1 Yan Yu
A1 Shujun Yang
A1 Xiaochun Zhang
A1 Guojun Zhang
A1 Yueyin Pan
A1 Sanyuan Sun
A1 Chengzhi Zhou
A1 Wei Hong
A1 Hui Zhao
A1 Lei Yang
A1 Linian Huang
A1 Rong Wu
A1 Aimin Zang
A1 Rui Ma
A1 Lin Wu
A1 Dongqing Lv
A1 Xiuhua Fu
A1 Jianguo Han
A1 Wenxin Li
A1 Jianchun Duan
A1 Kai Wang
A1 Ou Jiang
A1 Yinglan Chen
A1 Zhongliang Guo
A1 Hongjun Gao
A1 Juyi Wen
A1 Shubin Wang
A1 Enfeng Zhao
A1 Gaofeng Li
A1 Lu Yue
A1 Li Liang
A1 Aiping Zeng
A1 Xiaoshan Wang
A1 Yuxi Zhu
A1 Hongming Pan
A1 Zhaoxia Dai
A1 Weineng Feng
A1 Guofang Zhao
A1 Chuan Lin
A1 Chong Li
A1 Na Li
A1 Yangyi Bao
A1 Yinyin Li
A1 Yanjun Su
A1 Min Zhao
A1 Haohui Fang
A1 Yulong Zhu
A1 Yu Zhang
A1 Lieming Ding
A1 Yang Wang
A1 Xiaobin Yuan
A1 Jie Wang
PB Elsevier
YR 2021
K1 MIL60
K1 biosimilar
K1 bevacizumab
K1 equivalence
K1 non-squamous NSCLC
K1 Medicine (General)
K1 R5-920
JF http://www.sciencedirect.com/science/article/pii/S2589537021004685
LK http://dx.doi.org/https://doi.org/10.1016/j.eclinm.2021.101187
DO https://doi.org/10.1016/j.eclinm.2021.101187
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)